Basic Neurosciences, Instituto Nacional de Rehabilitación LGII, Mexico City 14389, Mexico.
Research Department, Universidad Estatal del Valle de Ecatepec, Ecatepec de Morelos 55210, Mexico.
Int J Mol Sci. 2023 Feb 10;24(4):3574. doi: 10.3390/ijms24043574.
The ongoing pandemic of COVID-19 has caused more than 6.7 million tragic deaths, plus, a large percentage of people who survived it present a myriad of chronic symptoms that last for at least 6 months; this has been named as long COVID. Some of the most prevalent are painful symptoms like headache, joint pain, migraine, neuropathic-like pain, fatigue and myalgia. MicroRNAs are small non-coding RNAs that regulate genes, and their involvement in several pathologies has been extensively shown. A deregulation of miRNAs has been observed in patients with COVID-19. The objective of the present systematic review was to show the prevalence of chronic pain-like symptoms of patients with long COVID and based on the expression of miRNAs in patients with COVID-19, and to present a proposal on how they may be involved in the pathogenic mechanisms of chronic pain-like symptoms. A systematic review was carried out in online databases for original articles published between March 2020 to April 2022; the systematic review followed the PRISMA guidelines, and it was registered in PROSPERO with registration number CRD42022318992. A total of 22 articles were included for the evaluation of miRNAs and 20 regarding long COVID; the overall prevalence of pain-like symptoms was around 10 to 87%, plus, the miRNAs that were commonly up and downregulated were miR-21-5p, miR-29a,b,c-3p miR-92a,b-3p, miR-92b-5p, miR-126-3p, miR-150-5p, miR-155-5p, miR-200a, c-3p, miR-320a,b,c,d,e-3p, and miR-451a. The molecular pathways that we hypothesized to be modulated by these miRNAs are the IL-6/STAT3 proinflammatory axis and the compromise of the blood-nerve barrier; these two mechanisms could be associated with the prevalence of fatigue and chronic pain in the long COVID population, plus they could be novel pharmacological targets in order to reduce and prevent these symptoms.
正在持续的 COVID-19 大流行已导致超过 670 万人悲惨死亡,此外,很大比例的幸存者都出现了至少持续 6 个月的多种慢性症状;这被称为长新冠。其中一些最常见的症状是疼痛,如头痛、关节痛、偏头痛、神经痛样疼痛、疲劳和肌痛。microRNAs 是调节基因的小非编码 RNA,其在多种疾病中的作用已得到广泛证实。在 COVID-19 患者中观察到 microRNAs 的失调。本系统评价的目的是展示长新冠患者慢性疼痛样症状的流行情况,并根据 COVID-19 患者 microRNAs 的表达情况,提出一个关于它们如何参与慢性疼痛样症状发病机制的建议。对 2020 年 3 月至 2022 年 4 月期间发表的原始文章进行了在线数据库的系统评价;系统评价遵循 PRISMA 指南,并在 PROSPERO 中以注册号 CRD42022318992 进行了注册。共纳入 22 篇评估 microRNAs 的文章和 20 篇关于长新冠的文章;疼痛样症状的总体患病率约为 10%至 87%,同时,常见的上调和下调的 microRNAs 是 miR-21-5p、miR-29a、b、c-3p、miR-92a、b-3p、miR-92b-5p、miR-126-3p、miR-150-5p、miR-155-5p、miR-200a、c-3p、miR-320a、b、c、d、e-3p 和 miR-451a。我们假设这些 microRNAs 调节的分子途径是 IL-6/STAT3 促炎轴和血-神经屏障的损害;这两个机制可能与长新冠人群中疲劳和慢性疼痛的流行有关,并且它们可能是减少和预防这些症状的新的药理学靶点。